Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24061674 | 0.85 | BTK (0.40) | BTKDPP4DPP8DPP7ELANE | |
| SCHEMBL17660274 | 0.82 | RAB9A (0.40) | BTKDPP4DPP8DPP7HDAC4 | |
| SCHEMBL21366084 | 0.80 | DPP4 (0.38) | BTKDPP4DPP8DPP7CTSL | |
| SCHEMBL17664593 | 0.79 | DPP4 (0.40) | BTKDPP4DPP8DPP7ELANE | |
| SCHEMBL13631414 | 0.77 | ALDH1A1 (0.38) | DPP4DPP8DPP7MAPK1 | |
| SCHEMBL11418825 | 0.75 | ALDH1A1 (0.33) | MAPK1 | |
| SCHEMBL17645774 | 0.74 | DPP4 (0.39) | DPP4DPP8DPP7CTSLCTSB | |
| SCHEMBL8840142 | 0.74 | PTPN1 (0.39) | BTKDPP4DPP8DPP7ELANE | |
| SCHEMBL12734314 | 0.74 | DPP4 (0.37) | BTKDPP4DPP8DPP7ELANE | |
| SCHEMBL21538962 | 0.72 | BTK (0.36) | BTKDPP4DPP8DPP7ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BTK 1/4885DPP4 2792/4885DPP8 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.